Frankfurt - Delayed Quote EUR

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (R9Z.F)

1.7400
+0.2300
+(15.23%)
At close: June 10 at 7:57:17 PM GMT+2
Currency in CNY All numbers in thousands
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
74,149
74,149
386
538
5,067
Operating Expense
382,192
382,192
391,035
382,714
220,418
Operating Income
-308,043
-308,043
-390,649
-382,176
-215,351
Net Non Operating Interest Income Expense
2,927
2,927
9,275
8,718
749
Pretax Income
-316,590
-316,590
-379,459
-402,894
-732,949
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-315,855
-315,855
-379,459
-402,894
-732,949
Diluted NI Available to Com Stockholders
-315,855
-315,855
-379,459
-402,894
-732,949
Basic EPS
-0.84
--
-1.05
-1.08
-1.96
Diluted EPS
-0.84
--
-1.05
-1.08
-1.96
Basic Average Shares
377,155
--
361,810
373,239.8950
373,239.8950
Diluted Average Shares
377,155
--
361,810
373,239.8950
373,239.8950
Total Expenses
382,192
382,192
391,035
382,714
220,418
Net Income from Continuing & Discontinued Operation
-315,855
-315,855
-379,459
-402,894
-732,949
Normalized Income
-302,608
-302,608
-381,220
-402,894
-735,267
Interest Income
6,376
6,376
10,799
9,505
1,640
Interest Expense
3,449
3,449
1,524
787
891
Net Interest Income
2,927
2,927
9,275
8,718
749
EBIT
-313,141
-313,141
-377,935
-402,107
-732,058
EBITDA
-292,460
-292,460
-355,352
-384,490
-718,882
Reconciled Depreciation
20,681
20,681
22,583
17,617
13,176
Net Income from Continuing Operation Net Minority Interest
-315,855
-315,855
-379,459
-402,894
-732,949
Total Unusual Items Excluding Goodwill
-13,247
-13,247
1,761
0
2,318
Total Unusual Items
-13,247
-13,247
1,761
0
2,318
Normalized EBITDA
-279,213
-279,213
-357,113
-384,490
-721,200
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 8/14/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers